324 related articles for article (PubMed ID: 31561030)
1. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: Improve SCA clinical trial.
Zhang S; Ching CK; Huang D; Liu YB; Rodriguez-Guerrero DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Lexcen DR; Muckala K; Brown ML; Cheng A; Singh B;
Heart Rhythm; 2020 Mar; 17(3):468-475. PubMed ID: 31561030
[TBL] [Abstract][Full Text] [Related]
2. Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design.
Zhang S; Singh B; Rodriguez DA; Chasnoits AR; Hussin A; Ching CK; Huang D; Liu YB; Cerkvenik J; Willey S; Kim YH
Europace; 2015 Nov; 17(11):1720-6. PubMed ID: 26037794
[TBL] [Abstract][Full Text] [Related]
3. Improving the utilization of implantable cardioverter defibrillators for sudden cardiac arrest prevention (Improve SCA) in developing countries: Clinical characteristics and reasons for implantation refusal.
Singh B; Zhang S; Ching CK; Huang D; Liu YB; Rodriguez DA; Hussin A; Kim YH; Chasnoits AR; Cerkvenik J; Muckala KA; Cheng A
Pacing Clin Electrophysiol; 2018 Dec; 41(12):1619-1626. PubMed ID: 30320410
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.
Holbrook R; Higuera L; Wherry K; Phay D; Hsieh YC; Lin KH; Liu YB
PLoS One; 2020; 15(11):e0241697. PubMed ID: 33211698
[TBL] [Abstract][Full Text] [Related]
5. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
6. Competing risks in patients with primary prevention implantable cardioverter-defibrillators: Global Electrical Heterogeneity and Clinical Outcomes study.
Waks JW; Haq KT; Tompkins C; Rogers AJ; Ehdaie A; Bender A; Minnier J; Dalouk K; Howell S; Peiris A; Raitt M; Narayan SM; Chugh SS; Tereshchenko LG
Heart Rhythm; 2021 Jun; 18(6):977-986. PubMed ID: 33684549
[TBL] [Abstract][Full Text] [Related]
7. Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators.
Lee DS; Hardy J; Yee R; Healey JS; Birnie D; Simpson CS; Crystal E; Mangat I; Nanthakumar K; Wang X; Krahn AD; Dorian P; Austin PC; Tu JV;
Circ Heart Fail; 2015 Sep; 8(5):927-37. PubMed ID: 26224792
[TBL] [Abstract][Full Text] [Related]
8. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
9. Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study.
Singh B; Hsieh YC; Liu YB; Lin KH; Joung B; Rodriguez DA; Chasnoits AR; Huang D; Zhang S; O'Brien JE; Lexcen DR; Cerkvenik J; Van Dorn B; Ching CK
Indian Heart J; 2023; 75(2):115-121. PubMed ID: 36736459
[TBL] [Abstract][Full Text] [Related]
10. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
11. Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.
Zhou Y; Zhao S; Chen K; Hua W; Su Y; Chen S; Liang Z; Xu W; Zhang S
BMC Cardiovasc Disord; 2019 Oct; 19(1):230. PubMed ID: 31638918
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the Improve SCA study.
Higuera L; Holbrook R; Wherry K; Rodriguez DA; Cuesta A; Valencia J; Arcos J; López Gómez A
J Med Econ; 2021; 24(1):173-180. PubMed ID: 33471579
[TBL] [Abstract][Full Text] [Related]
13. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD).
Vehmeijer JT; Koyak Z; Leerink JM; Zwinderman AH; Harris L; Peinado R; Oechslin EN; Robbers-Visser D; Groenink M; Boekholdt SM; de Winter RJ; Oliver JM; Bouma BJ; Budts W; Van Gelder IC; Mulder BJM; de Groot JR
Heart Rhythm; 2021 May; 18(5):785-792. PubMed ID: 33465514
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
[TBL] [Abstract][Full Text] [Related]
15. Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD).
Cheng A; Zhang Y; Blasco-Colmenares E; Dalal D; Butcher B; Norgard S; Eldadah Z; Ellenbogen KA; Dickfeld T; Spragg DD; Marine JE; Guallar E; Tomaselli GF
Circ Arrhythm Electrophysiol; 2014 Dec; 7(6):1084-91. PubMed ID: 25273351
[TBL] [Abstract][Full Text] [Related]
16. Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure.
Chia YMF; Teng TK; Tan ESJ; Tay WT; Richards AM; Chin CWL; Shimizu W; Park SW; Hung CL; Ling LH; Ngarmukos T; Omar R; Siswanto BB; Narasimhan C; Reyes EB; Yu CM; Anand I; MacDonald MR; Yap J; Zhang S; Finkelstein EA; Lam CSP
Circ Cardiovasc Qual Outcomes; 2017 Nov; 10(11):. PubMed ID: 29150533
[TBL] [Abstract][Full Text] [Related]
17. Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.
Hoang A; Shen C; Zheng J; Taylor S; Groh WJ; Rosenman M; Buxton AE; Chen PS
Heart Rhythm; 2014 May; 11(5):849-55. PubMed ID: 24566233
[TBL] [Abstract][Full Text] [Related]
18. Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation.
Fauchier L; Marijon E; Defaye P; Piot O; Sadoul N; Perier MC; Gras D; Klug D; Algalarrondo V; Bordachar P; Deharo JC; Leclercq C; Babuty D; Boveda S;
Am J Cardiol; 2015 May; 115(10):1415-22. PubMed ID: 25784518
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD).
Zhang Y; Kennedy R; Blasco-Colmenares E; Butcher B; Norgard S; Eldadah Z; Dickfeld T; Ellenbogen KA; Marine JE; Guallar E; Tomaselli GF; Cheng A
Heart Rhythm; 2014 Aug; 11(8):1377-83. PubMed ID: 24793459
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Pediatric Patients With Defibrillators Following Initial Presentation With Sudden Cardiac Arrest.
Robinson JA; LaPage MJ; Atallah J; Webster G; Miyake CY; Ratnasamy C; Ollberding NJ; Mohan S; Von Bergen NH; Johnsrude CL; Garnreiter JM; Spar DS; Czosek RJ
Circ Arrhythm Electrophysiol; 2021 Feb; 14(2):e008517. PubMed ID: 33401923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
